arvinas_logoART_lg.jpg
Arvinas Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update
February 11, 2025 07:00 ET | Arvinas Inc.
– Announced that topline data from the monotherapy Phase 3 VERITAC-2 trial is anticipated in 1Q25 – – Presented Phase 1b data from the TACTIVE-U sub-study of vepdegestrant in...
arvinas_logoART_lg.jpg
Arvinas to Report Fourth Quarter and Full Year 2024 Financial Results on Tuesday, February 11, 2025
February 03, 2025 07:00 ET | Arvinas Inc.
NEW HAVEN, Conn., Feb. 03, 2025 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today...
scichart logo dark light-03 - 300dpi.png
From Data to Movement: The Breakthrough Helping Paralyzed Patients Walk Again
January 16, 2025 08:00 ET | SciChart
From Data to Movement: NeuroRestore, powered by SciChart, combines spinal stimulation with real-time data to help paralyzed patients walk again.
Patient's progress during Epidural Electrical Stimulation (EES) therapy, visualized with NeuroRestore powered by SciChart, showing walking stages and
From Data to Movement: The Breakthrough Helping Paralyzed Patients Walk Again
January 16, 2025 04:04 ET | SciChart
From Data to Movement: NeuroRestore, powered by SciChart, combines spinal stimulation with real-time data to help paralyzed patients walk again.
Alliance Logo.jpg
Alliance for Decision Education Launches Season 5 of The Decision Education Podcast
January 15, 2025 10:07 ET | Alliance for Decision Education
The Alliance for Decision Education announces Season 5 of The Decision Education Podcast, featuring renowned experts and host Annie Duke.
arvinas_logoART_lg.jpg
Arvinas Updates Guidance for First- and Second-Line Phase 3 Combination Trials with Vepdegestrant, Highlights Upcoming Milestones, and Provides Corporate Update
January 10, 2025 07:00 ET | Arvinas Inc.
– Vepdegestrant to be combined with Pfizer’s novel investigational CDK4 inhibitor atirmociclib in a first-line Phase 3 trial planned to initiate in 2025; a second-line Phase 3 combination trial will...
© 2025 IOB, all rights reserved.
Breakthrough Gene Editing Technique Offers Hope for Stargardt Disease Patients Researchers have developed a highly efficient gene editing therapy that could potentially treat Stargardt disease, the most common form of inherited macular degeneration. This groundbreaking study,...
Firefly.png
Firefly Neuroscience Closes on Financing of up to $12.4 Million
December 31, 2024 09:00 ET | Firefly Neuroscience, Inc.
TORONTO, Dec. 31, 2024 (GLOBE NEWSWIRE) -- Firefly Neuroscience, Inc. (“Firefly,” “we,” or the “Company”) (NASDAQ: AIFF), an Artificial Intelligence (“AI”) company developing innovative solutions...
NOVARTIS logo.jpg
Novartis intrathecal onasemnogene abeparvovec Phase III study meets primary endpoint in children and young adults with SMA
December 30, 2024 00:45 ET | Novartis Pharma AG
Ad hoc announcement pursuant to Art. 53 LR The Phase III STEER study met its primary endpoint showing an increase from baseline in HFMSE total score in patients with SMA...
PN LOGO.jpg
Precision Neuroscience Raises $102 Million to Advance AI-Powered Brain Implant
December 16, 2024 07:00 ET | Precision Neuroscience
The raise brings Precision’s total funding to $155 million, solidifying its position as a leader in the brain–computer interface industry.Investors include General Equity Holdings, B Capital, Stanley...